The DOI matches its Crossref record.
Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival
Abstract
In recent years, reagents have been developed that specifically target signals critical for effective T cell activation and function. Manipulation of the CD28/CD80/86 and CD40/CD154 pathways has exhibited extraordinary efficacy, particularly when the pathways are blocked simultaneously. Despite the reported efficacy of anti-CD154 in rodents and higher models, its future clinical use is uncertain due to reported thromboembolic events in clinical trials. To circumvent this potential complication, we developed and evaluated a chimeric Ab targeting CD40 (Chi220, BMS-224819) as an alternative to CD154. Although Chi220 blocks CD154 binding, it also possesses partial agonist properties and weak stimulatory potential. The anti-CD40 was tested alone and in combination with a rationally designed, high affinity variant of CTLA4-Ig, LEA29Y (belatacept), in a nonhuman primate model of islet transplantation. Although either agent alone only modestly prolonged islet survival (Chi220 alone: 14, 16, and 84 days; LEA29Y alone: 58 and 60 days), their combination (LEA29Y and Chi220) dramatically facilitated long term survival (237, 237, 220, >185, and 172 days). We found that the effects of Chi220 treatment were not mediated solely through deletion of CD20-bearing cells and that the combined therapy did not significantly impair established antiviral immunity.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
International trial of the Edmonton protocol for islet transplantation
Shapiro, A. M. J., Ricordi, C., Hering, B. J., Auchincloss, H., Lindblad, R., Robertson, R. P., Secchi, A., Brendel, M. D., Berney, T., Brennan, D. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061267 · Cited by 1,942
Cardona, K., Korbutt, G. S., Milas, Z., Lyon, J., Cano, J., Jiang, W., Bello-Laborn, H., Hacquoil, B., Strobert, E., Gangappa, S., et al. (2006) · Nature Medicine · doi:10.1038/nm1375 · Cited by 477
Self-citationCTLA4Ig: Bridging the Basic Immunology with Clinical Application
Bluestone, J. A., St. Clair, E. W., & Turka, L. A. (2006) · Immunity · doi:10.1016/j.immuni.2006.03.001 · Cited by 276
High Risk of Sensitization After Failed Islet Transplantation
Campbell, P. M., Senior, P. A., Salam, A., LaBranche, K., Bigam, D. L., Kneteman, N. M., Imes, S., Halpin, A., Ryan, E. A., & Shapiro, A. M. J. (2007) · American Journal of Transplantation · doi:10.1111/j.1600-6143.2007.01923.x · Cited by 173
Metadata
- Authors
- Adams, A. B., Shirasugi, N., Jones, T. R., Durham, M. M., Strobert, E. A., Cowan, S., Rees, P., Hendrix, R., Price, K., Kenyon, N. S., Hagerty, D., Townsend, R., Hollenbaugh, D., Pearson, T. C., & Larsen, C. P.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2005-01-01
- Volume
- 174
- Issue
- 1
- Pages
- 542-550
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1623137528
- Cited by
- 183
- References
- 0
- FWCI
- 6.44
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival. https://app.cochat.ai/papers/10.4049/jimmunol.174.1.542
- The paper
- Adams, A. B., Shirasugi, N., Jones, T. R., Durham, M. M., Strobert, E. A., Cowan, S., Rees, P., Hendrix, R., Price, K., Kenyon, N. S., Hagerty, D., Townsend, R., Hollenbaugh, D., Pearson, T. C., & Larsen, C. P. (2005). Development of a Chimeric Anti-CD40 Monoclonal Antibody That Synergizes with LEA29Y to Prolong Islet Allograft Survival. The Journal of Immunology. https://doi.org/10.4049/jimmunol.174.1.542
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.